[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hasanuddin University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100629801","phase-4-impact-of-ahcc-supplementation-for-prevention-of-respiratory-tract-infections-among-children-age-2-4-years-old-100629801",false,"NCT07479394","Impact of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 2-4 Years Old","A Double-Blind, Randomized, Placebo-Controlled Trial of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 2-4 Years Old","Inclusion Criteria:\n\n1. Children aged 2-4 years old at the time of enrolment\n2. Good nutritional status with weight-for-height \\> -2, and height-for-age z-score \\> -2 based on WHO growth standards\n3. Infants in a group setting (daycare centers).\n4. No congenital disorder\n5. Not suffering from severe coughing or diarrhoea at the time of recruitment\n6. Written informed consent will be obtained from parents or legal guardians before enrollment.\n\nExclusion Criteria:\n\n* Presence of chronic illnesses or conditions (congenital disorder, genetic syndromes, congenital heart disease, chronic renal failure, cystic fibrosis, etc)\n* Children who have participated in another clinical intervention study within the past 30 days.\n* Children who are likely to be transferred to another facility that is not part of the study before completing the follow-up period",true,"ALL","2 Years","4 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a study to evaluate the effects of a prebiotic, AHCC, a standardized extract of cultured Lentinula edodes mycelia, on immunologic markers and the incidence of respiratory tract infections in children.",[28],"Respiratory Tract Infections (RTI)",[30,31,32,33],"AHCC","Lentinula edodes mycelia","prebiotic","respiratory tract infection (RTI)","NOT_YET_RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":22},"2026-06-01",{"date":42,"type":22},"2026-12-31",{"name":44,"class":45},"Hasanuddin University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100605685","virtual-health-coaching-with-artificial-intelligence-for-glycemic-control-in-type-2-diabetes-100605685","NCT07165730","Virtual Health Coaching With Artificial Intelligence for Glycemic Control in Type 2 Diabetes","Effectiveness of Virtual Health Coaching Based on Artificial Intelligence to Improve Glycemic Control in Patients With Type 2 Diabetes Mellitus","DIACOACH-AI","Inclusion Criteria:\n\nDiagnosed with Type 2 Diabetes Mellitus for more than 3 months\n\nAge between 30 and 56 years\n\nAble to read and understand instructions\n\nHave access to a digital device (smartphone or similar)\n\nIn stable clinical condition\n\nExclusion Criteria:\n\nDiagnosed with Type 1 Diabetes Mellitus\n\nPatients with severe complications (e.g., advanced nephropathy, retinopathy, cardiovascular disease)\n\nPatients currently undergoing other structured interventions\n\nPatients on long-term steroid therapy\n\nPatients without access to a digital device","18 Years","65 Years",{"count":57,"type":22},206,[59],"NA","This study aims to evaluate the effectiveness of a virtual health coaching program based on artificial intelligence (AI) in improving blood sugar control among people with type 2 diabetes in primary health care settings in Jeneponto and Bantaeng, Indonesia. The intervention will be delivered through the DIACOACH application, which provides personalized coaching, lifestyle guidance, and self-care support. Participants will be randomly assigned to either the intervention group, receiving virtual health coaching for 12 weeks, or the control group, receiving standard diabetes education. Main outcomes include fasting blood sugar and HbA1c levels. Other outcomes include self-care adherence, dietary behavior, and quality of life. This trial seeks to provide evidence on whether AI-based virtual coaching is a practical and effective digital health solution to support diabetes self-management in community health settings with limited resources.",[62],"Type 2 Diabetes Mellitus (T2DM)",[64,65,66],"Virtual Health Coaching","Artificial Intelligence (AI)","Glycemic Control","2025-09-03",{"date":69,"type":38},"2025-09-10",{"date":71,"type":22},"2025-09-15",{"date":73,"type":22},"2026-06-15",{"name":44,"class":45},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100566761","probiotic-efficacy-in-postmenopausal-women-with-bacterial-vaginosis-100566761","NCT06659380","Probiotic Efficacy in Postmenopausal Women with Bacterial Vaginosis","Modulation of Vaginal Microbiota by Lactobacillus Sp As a Probiotic and Immunomodulatory Agent in Postmenopausal Women with Bacterial Vaginosis","Inclusion Criteria:\n\n1. Postmenopausal with estradiol levels \\\u003C 25 mg\u002Fml\n2. Diagnosed have bacterial vaginosis by an obstetrician and gynecologist\n\nExclusion Criteria:\n\n1. Medically unable to perform a pap smear examination\n2. Experiencing vaginal bleeding of unknown cause\n3. Diagnosed or suspected of having a malignant disease\n4. Hypersensitivity to the research treatment to be carried out\n5. In the last 3 months have received hormone therapy\n6. Suffering from acute infectious diseases of the genital organs\n7. Using vaginal therapy in any form\n8. Suffering from systemic diseases","FEMALE",{"count":85,"type":22},12,[59],"This study is a double-blind, randomized, controlled trial (RCT) aimed at evaluating the effects of Lactobacillus sp. probiotic administration on the vaginal microbiota changes in postmenopausal women with bacterial vaginosis and how its affect to immunology profile. Postmenopausal women diagnosed with bacterial vaginosis will be recruited as subjects as long as collected period in this study. All patients will receive Metronidazole antibiotic treatment then blind-randomly be divided into two groups: the treatment group, receiving Floragyn® probiotic tablets (Lapi, Indonesia), and the placebo group, receiving Cal 95® (Lapi, Indonesia). As a control, postmenopausal women without bacterial vaginosis will also be included and receive Floragyn® probiotic tablets only.",[89,90],"Bacterial Vaginosis (BV)","Menopause",[92],"NO","RECRUITING","2024-10-24",{"date":96,"type":38},"2024-10-28",{"date":98,"type":38},"2024-06-26",{"date":100,"type":22},"2024-12-31",{"name":44,"class":45},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100559367","exergame-and-robotic-therapy-impact-on-tenascin-c-and-functional-outcome-on-stroke-patients-100559367","NCT06563206","Exergame and Robotic Therapy Impact on Tenascin-C and Functional Outcome on Stroke Patients","Comparison of Tenascin-C Value Rates and Functional Outcomes Between Exergame Therapy and Robotic Therapy in Post-Stroke Patients","Inclusion Criteria:\n\n* Patients after ischemic or hemorrhagic stroke\n* stable hemodynamics and neurologic state.\n* Patients have never undergone treatment with any intervention\n* Able to watch television with or without glasses from a distance of 1 meter.\n* Patients can understand informed consent to participate in research\n\nExclusion Criteria:\n\n* Patients with a history of seizures or epilepsy.\n* Patients with severe cognitive disorders that can interfere with research objectives (MMSE score \\\u003C24).\n* Patients with field deficits or severe vision disorders.\n* The patient is unable to sit upright without help.\n* Patients with significant pain in the affected upper limb.\n* Patients with significant sensory decreases in the upper limb that are affected\n* Patients with other medical conditions (musculoskeletal, neuromuscular, cardio respiration) are uncontrolled and are at risk of disrupting the ability to exercise.\n\nDropout Criteria\n\n* Patients who were declared dead\n* Refusing to continue the training session or less \\\u003C 50% of all sessions.\n* Experiencing hemodynamic and neurological disorders during the training program process.\n* Experiencing cybersickness twice in successive training sessions",{"count":110,"type":22},48,[59],"This clinical trial aims to compare the effectiveness of Robotic versus Exergame versus Standard therapy to improve hand function among post-stroke patients. The main questions it aims to answer are:\n\n1, Effectiveness of interventions in functional outcome recovery across time 2. Effectiveness of interventions in affecting Tenascin-C level 3. Clinical outcome difference between all interventions\n\nParticipants will be allocated into three groups, either a robotic group, exergame group as the main interventions, and standard rehabilitation group as the active comparator. A serial follow-up will be conducted to assess the selected clinical outcome and differences in outcome",[114,115],"Stroke","Paralysis Arm",[117,118,119,120,121],"Robotic Rehabilitation","Video-assisted Rehabilitation","Post-Stroke","Functional Outcome","Tenascin-C","2024-08-17",{"date":124,"type":38},"2024-08-20",{"date":126,"type":38},"2023-10-01",{"date":128,"type":22},"2025-03-01",{"name":44,"class":45},2,""]